This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body. This cancer can be hard to treat because it can behave differently from one person to another. Over time, treatments may stop working, and side effects can build up. In later treatment stages, there are only a few standard medicine options available. Because of this, studies often look at both how long people live and how treatment affects quality of life.
The main aim of this study is to see how long adults in Poland with mCRC live without their cancer getting worse (progression-free survival or PFS) when they receive fruquintinib after at least two previous treatments. Fruquintinib (TAK 113) is a medicine taken by mouth that is designed to slow tumor growth.
Other aim is to find out how long adults in Poland with mCRC live while being treated with fruquintinib (overall survival or OS). The study also wants to record how fruquintinib is used in routine care in adults with mCRC in Poland (for example when treatment starts, changes in doses, and how long treatment continues). Another aim is to learn about people with mCRC, such as their medical history and past treatment as well as their quality of life while they are in the study.
The study will look at data already existing in the participants' medical charts.
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion or MTAP loss after progression on prior therapies.
There is a lack of strategies for patients who progress after responding to PD-1/l-1 in melanoma. High expression of Nectin4 in skin and melanomas may serve as a new target in advanced melanomas. The combination of enfortumab/vedotin (EV) and pembrolizumab has shown synergistic effect in various solid tumors. Enfortumab vedotin and pembrolizumab may have a dual effect on clinical outcomes.
PLUGIN is a multicenter, non-randomized open-label, 2-cohort, phase 2 study to evaluate the ORR of pembrolizumab in combination with enfortumab vedotin (EV) in previously treated participants with unresectable stage III or IV melanoma and disease progression on standard therapy.
The primary objective is evaluate the efficacy of enfortumab/vedotin and pembrolizumabplus pembrolizumab in advanced melanoma.
Hypothesis: 1) High expression of Nectin4 in skin and melanomas may serve as a new target in advanced melanomas; 2)EV+Pembrolizumab has shown synergistic effect in various solid tumors; 3) There is a lack of strategies for patients who respond to PD1-mAbs in melanoma.
Primary Endpoint: Objective Response Rate (ORR) as assessed by the investigator according RECIST 1.1
A total of 60 patients will be enrolled in this study to evaluate efficacy and outcomes in two different cohorts:
Cohort 1: patients who did not have BRAF mutation V600E and had disease progression on immune (IO) therapy.
Cohort 2, patients with activating BRAF mutations, must have progressed on IO therapy and BRAF/MEKi
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
•Wiek co najmniej 18 lat z potwierdzonym czerniakiem, który nie można operować lub ma przerzuty
•Mierzalne ogniska nowotworu widoczne w badaniach
•Wcześniejsze leczenie systemowe (lekami ogólnoustrojowymi) z powodu zaawansowanego czerniaka
•Progresja choroby po leczeniu inhibitorami PD-1/L1 (co najmniej 2 dawki)
•Potwierdzenie progresji nowotworu w drugim badaniu nie wcześniej niż 4 tygodnie po pierwszym
•Mężczyźni: zgoda na antykoncepcję przez 9 miesięcy po ostatniej dawce lub 4 miesiące po pembrolizumabie
•Kobiety: mogą brać udział, jeśli nie są w ciąży, nie karmią piersią i stosują antykoncepcję przez 12 miesięcy po leczeniu
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.
Your privacy
We use Google Analytics to understand how you use our tools and to improve them. We don't collect health data and we don't show ads. You can decline - the site will work exactly the same. Privacy policy